HM-15421 Market Summary

Key Factors Driving HM-15421 Growth

1. Potential to reduce treatment frequency

Conventional enzyme replacement therapies for Fabry disease, such as agalsidase beta, are typically administered intravenously every two weeks. HM-15421 is designed as a long-acting enzyme replacement therapy administered by subcutaneous injection, potentially reducing infusion-related burden. If clinical trials establish that its extended action allows less frequent dosing while maintaining disease control, this could become a key driver of adoption.

2. Fc-fusion technology may extend enzyme half-life

HM-15421 combines alpha-galactosidase A with the Fc region of an immunoglobulin. The Fc component is intended to exploit the neonatal Fc receptor (FcRn) recycling pathway, potentially extending the enzyme's circulation time and improving its stability. This approach may help sustain enzyme availability and distinguish HM-15421 from conventional enzyme replacement products, although its clinical advantage must be confirmed in patient studies.

3. Unmet need in Fabry disease

Fabry disease causes progressive accumulation of glycosphingolipids, potentially leading to kidney failure, cardiac complications and neurological events. Despite available enzyme replacement and other disease-specific treatments, some patients continue to experience disease progression. A long-acting enzyme therapy that maintains adequate enzyme activity and improves treatment convenience could address an important unmet need.

4. Clinical development and patient recruitment

HM-15421/GC1134A is being evaluated in a first-in-human, open-label Phase 1/2 proof-of-concept study in adults with Fabry disease. The trial plans to enrol 18 patients across three sequential dose cohorts to evaluate safety, tolerability, pharmacokinetics and preliminary efficacy. The study began in May 2025, with primary completion and overall completion estimated for August 2028 in the available registry record. Successful dose selection and clinical results will be important catalysts for further development.

5. Potential subcutaneous administration advantage

Subcutaneous administration could make treatment more convenient than repeated intravenous infusions, potentially reducing time spent at infusion centres and simplifying treatment delivery. This could be particularly attractive for patients requiring lifelong therapy. However, the practical advantage will depend on the final dose volume, injection frequency, tolerability and whether the product can maintain effective enzyme activity in relevant tissues.

HM-15421 Recent Developments

In May 2024, the US Food and Drug Administration granted orphan drug designation to HM-15421 for Fabry disease.

“HM-15421 Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of HM-15421 for potential indication like Fabry’s disease in the 7MM. A detailed picture of HM-15421’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the HM-15421 for potential indications. The HM-15421 market report provides insights about HM-15421’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current HM-15421 performance, future market assessments inclusive of the HM-15421 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of HM-15421 sales forecasts, along with factors driving its market.

HM-15421 Drug Summary

HM-15421 (also known as GC-1134A or LA-GLA) is an investigational, long-acting enzyme replacement therapy being co-developed by Hanmi Pharmaceutical and GC Biopharma for the treatment of Fabry disease, a rare, inherited X-linked lysosomal storage disorder caused by mutations in the GLA gene that result in deficient alpha-galactosidase A (α-Gal A) enzyme activity and the accumulation of globotriaosylceramide (Gb3) and related glycosphingolipids in organs and tissues. HM-15421 is designed to supplement the deficient enzyme, enabling the breakdown of accumulated substrates and potentially reducing progressive damage to the kidneys, heart, blood vessels and nervous system. Its long-acting formulation is intended to enable once-monthly subcutaneous administration, potentially offering greater convenience than conventional enzyme replacement therapies that generally require intravenous infusions every two weeks. The therapy aims to provide sustained enzyme activity and improve treatment adherence while addressing the limitations associated with existing Fabry disease treatments. The report provides HM-15421’s sales, growth barriers and drivers, post usage and approvals in multiple indications.

Scope of the HM-15421 Market Report

The report provides insights into:

• A comprehensive product overview including the HM-15421 MoA, description, dosage and administration, research and development activities in potential indication like Fabry’s disease.
• Elaborated details on HM-15421 regulatory milestones and other development activities have been provided in HM-15421 market report.
• The report also highlights HM-15421‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The HM-15421 market report also covers the patents information, generic entry and impact on cost cut.
• The HM-15421 market report contains current and forecasted HM-15421 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The HM-15421 market report also features the SWOT analysis with analyst views for HM-15421 in potential indications.

Methodology

The HM-15421 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

HM-15421 Analytical Perspective by DelveInsight

• In-depth HM-15421 Market Assessment

This HM-15421 sales market forecast report provides a detailed market assessment of HM-15421 for potential indication like Fabry’s disease in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted HM-15421 sales data uptil 2034.

• HM-15421 Clinical Assessment

The HM-15421 market report provides the clinical trials information of HM-15421 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

HM-15421 Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

HM-15421 Market Potential & Revenue Forecast

• Projected market size for the HM-15421 and its key indications
• Estimated HM-15421 sales potential (HM-15421 peak sales forecasts)
• HM-15421 Pricing strategies and reimbursement landscape

HM-15421 Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• HM-15421 Market positioning compared to existing treatments
• HM-15421 Strengths & weaknesses relative to competitors

HM-15421 Regulatory & Commercial Milestones

• HM-15421 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

HM-15421 Clinical Differentiation

• HM-15421 Efficacy & safety advantages over existing drugs
• HM-15421 Unique selling points

HM-15421 Market Report Highlights

• In the coming years, the HM-15421 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The HM-15421 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence HM-15421’s dominance.
• Other emerging products for Fabry’s disease are expected to give tough market competition to HM-15421 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of HM-15421 in potential indications.
• Analyse HM-15421 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted HM-15421 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of HM-15421 in potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of HM-15421? How strong is HM-15421’s clinical and commercial performance?
• What is HM-15421’s clinical trial status in each individual indications such as Fabry’s disease and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the HM-15421 Manufacturers?
• What are the key designations that have been granted to HM-15421 for potential indications? How are they going to impact HM-15421’s penetration in various geographies?
• What is the current and forecasted HM-15421 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of HM-15421 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to HM-15421 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is HM-15421? What is the duration of therapy and what are the geographical variations in cost per patient?